Page 137 - NobleCon19revC2_Neat

NRx Pharmaceuticals, Inc.

SELECTED FINANCIAL ITEMS NRXP

(in millions of USD)
CQ4 '22 CQ1 '23 CQ2 '23 CQ3 '23 LTM
Income Statement Key Items
Total Revenue NA NA NA NA 0.00
Gross Profit NA NA NA NA 0.00
Gross Margin NM NM NM NM NM
EBIT (9.89) (9.44) (7.94) (5.81) (33.07)
EBIT Margin NM NM NM NM NM
Net Income to Common Shareholders (10.24) (11.04) (8.72) (6.06) (36.06)
Net Margin NM NM NM NM NM

Balance Sheet Key Items
Total Assets 25.82 21.78 19.81 13.11 13.11
Cash & Short Term Investments 20.05 16.51 14.97 8.90 8.90
% of Assets 78% 76% 76% 68% 68%
Current Assets -Total 25.80 21.76 19.79 13.09 13.09
% of Assets 100% 100% 100% 100% 100%
Total Liabilities 18.41 22.06 22.62 19.33 19.33
% of Assets 71% 101% 114% 147% 147%
Current Liabilities - Total 15.59 22.06 22.62 19.33 19.33
% of Assets 60% 101% 114% 147% 147%
Long Term Debt 2.82 NA NA NA NA
% of Assets 11% NM NM NM NM
Total Equity 7.41 (0.28) (2.81) (6.22) (6.22)
% of Assets 29% -1% -14% -47% -47%

Cash Flow Statement Key Items
Net Cash Flow - Operating Activities (8.32) (6.09) (7.81) (4.56) (26.78)
Net Cash Flow - Investing 0.00 (0.00) 0.00 (0.00) (0.00)
Net Cash Flow - Financing 10.12 2.55 6.27 (1.50) 17.44

Source: Capital IQ

PRICE / VOLUME

Source: Channelchek/QuoteMedia

Noble Capital Markets' Nineteenth Annual Small & Microcap Investor Conference